AIP insider Paul Alpern executed 5,000-share exercise and sale on 10/01/2025
Rhea-AI Filing Summary
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.
Positive
- Transaction executed under a 10b5-1 plan adopted on June 5, 2025, indicating pre-established trading instructions
- Sale price disclosed as a weighted average of $10.3089 with a reported per-trade range of $10.16–$10.51, providing transparency on execution
- Derivative option remains outstanding with exercisable date 10/01/2025 and expiration 10/23/2029, and 85,000 shares total beneficially owned including derivatives
Negative
- Non-derivative holdings decreased by 5,000 shares to 73,587 following the sale
- Multiple sales occurred (prices ranged across $10.16–$10.51), which may complicate simple interpretation of proceeds without per-trade breakdown
Insights
TL;DR: Insider exercised and immediately sold 5,000 shares under a pre-established 10b5-1 plan.
The report shows a concurrent exercise (or deemed acquisition) of 5,000 shares at $0.56 and a sale of 5,000 shares at a weighted average of $10.3089. The seller discloses the sale price range ($10.16–$10.51), which indicates the sale occurred in multiple transactions.
This was executed under a disclosed 10b5-1 trading plan adopted on June 5, 2025, which documents pre-clearance and timing rules reducing the likelihood of impermissible insider trading claims.
TL;DR: Insider holdings remain material but were modestly reduced after the trade.
Non-derivative beneficial ownership following the reported transactions is 73,587 shares; including derivative securities the filing lists 85,000 shares beneficially owned. The filing also discloses a vesting schedule for the derivative shares that began vesting on August 26, 2020 with monthly vesting thereafter.
Filing is signed and dated 10/03/2025, providing an auditable record of the insider's activity as required under Section 16.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Common Stock | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.56 | $3K |
| Sale | Common Stock | 5,000 | $10.3089 | $52K |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 5, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.51 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26,2020.
